Latest Diagnostics News

Mach7 Technologies has initiated Phase 1 of the Veterans Health Administration’s National Teleradiology Program, deploying its core imaging software across 125 sites. This milestone sets the stage for a potential $11.7 million contract and broader expansion within the VHA network.

TrivarX has reported promising interim results from its US veteran-focused mental health trial using ECG technology, while progressing a strategic acquisition of novel brain tumor imaging IP to broaden its diagnostic portfolio.

Echo IQ Limited has advanced its EchoSolv heart failure solution towards FDA submission, driven by a landmark clinical validation study and a sharp rise in US platform adoption. Strategic partnerships and international expansion efforts underscore the company’s growing footprint in cardiology AI.

4DMedical Limited has secured FDA clearance and immediate Medicare reimbursement for its groundbreaking CT – VQ™ lung imaging technology, accelerating commercial adoption across the US, Brazil, and Australia.

Cleo Diagnostics has successfully completed Stage 1 of the Medical Device Single Audit Program, marking a significant step toward FDA submission and global commercialisation of its ovarian cancer test.

Resonance Health reports positive cash flow and significant progress in its clinical trials and Software-as-a-Medical Device business, setting the stage for growth in new international markets.

Atomo Diagnostics reported strong commercial momentum in Q1 FY26, highlighted by a key FDA submission for its FebriDx test and a successful capital raise of $1.3 million. The company also showcased promising clinical data for its Active Syphilis test and expanded its HIV Self-Test distribution channels.

BlinkLab has completed its U.S. autism pilot study with strong diagnostic accuracy and expanded its pivotal FDA trial to seven leading research centers, positioning itself for regulatory submission in late 2026.

Archer Materials has successfully demonstrated that its blood potassium Biochip can be fabricated on a silicon platform, matching clinical accuracy standards and accelerating its path to commercialisation.

Rhythm Biosciences reports strong Q1 FY26 progress, securing strategic partnerships and advancing commercial readiness for its ColoSTAT® colorectal cancer test alongside robust growth in its geneType platform.

INOVIQ Limited has raised $9.5 million to advance its pioneering ovarian cancer screening test and CAR-exosome therapeutic programs, backed by strong preclinical data and strategic partnerships.

Medibank has set ambitious goals to triple its health segment earnings by FY30, expand its private health insurance market share, and double its health engagement, signaling a strategic pivot towards integrated, technology-driven care.